Skip to main content
Medical information Clinical review pending

Genetic Testing

SETX Gene Ataxia-Oculomotor Apraxia Type 2 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to analyze the SETX gene for mutations associated with Ataxia-Oculomotor Apraxia Type 2, a neurological disorder. Helps in diagnosis and understanding genetic predispositions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (usually collected in an EDTA tube). Confirm with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this test. However, confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SETX Gene Ataxia-Oculomotor Apraxia Type 2 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms of ataxia (uncoordinated movements)
  • ✓Symptoms of oculomotor apraxia (difficulty with eye movements)
  • ✓Family history of Ataxia-Oculomotor Apraxia Type 2
  • ✓Progressive loss of motor skills
  • ✓Diagnosis of a neurological disorder of unknown origin
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the SETX gene associated with Ataxia-Oculomotor Apraxia Type 2. It aids in confirming a diagnosis, understanding the genetic basis of the condition, and potentially guiding treatment strategies. Results can also inform genetic counseling for affected individuals and their families.
The SETX Gene Ataxia-Oculomotor Apraxia Type 2 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to neurological conditions. This test utilizes Next-Generation Sequencing (NGS) technology for a detailed analysis of the SETX gene. Mutations in this gene are associated with Ataxia-Oculomotor Apraxia Type 2. Understanding your genetic makeup can provide valuable information for managing your health and potential treatment options. This test analyzes your DNA to detect specific variations in the SETX gene that may be causing neurological symptoms. It is particularly relevant for individuals experiencing symptoms related to ataxia or oculomotor apraxia, or those with a family history of similar neurological disorders.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this test. However, confirm with the laboratory before booking.
SampleBlood sample (usually collected in an EDTA tube). Confirm with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the SETX gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the SETX gene. It may not detect mutations in other genes that could cause similar symptoms. A negative result does not completely rule out a genetic cause for the condition. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is a rare neurological disorder characterized by progressive ataxia (problems with coordination and balance) and oculomotor apraxia (difficulty voluntarily moving the eyes).
Individuals experiencing symptoms like uncoordinated movements, difficulty with eye movements, or a family history of similar neurological conditions should discuss this test with their doctor.
A blood sample is typically required for this test. We offer sample collection at our branches or through a home collection service in major cities.
The turnaround time is generally 3 to 4 weeks, but this can vary. Confirm with the laboratory before booking.
Your doctor or a genetic counselor will help interpret the results and discuss their implications for your health and potential next steps.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp